Developer docs
API playgroundTry for free, no card

Search company profiles

Greywolf Therapeutics

Full company profile

uuid0000oj2

Namestring
Greywolf Therapeutics
Legal namestring
Grey Wolf Therapeutics Limited
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Greywolf Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Abingdon, UK, developing first-in-class oral small molecule inhibitors of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) — a novel antigen modulation approach that targets Signal 1 of T-cell activation, the initial step of antigen recognition that has been therapeutically unexplored to date. By inhibiting ERAP1, the company alters the peptide repertoire presented on MHC-I molecules, creating novel immunogenic peptides in oncology (making tumor cells more visible to the immune system) and suppressing autoantigen presentation in autoimmune disease. The pipeline comprises two clinical-stage assets: GRWD5769, an oral ERAP1 inhibitor in Phase 1/2 development (EMITT-1 trial) in combination with cemiplimab across six solid tumor indications including NSCLC, urothelial carcinoma, HCC, MSS-CRC, SCCHN and cervical cancer, demonstrating objective response rates of 13-36% in patients with secondary anti-PD-1 resistance; and GRWD0715, a selective ERAP1 inhibitor in Phase 1/2 (EAST-1) for axial spondyloarthritis. The company also has discovery programs targeting ERAP2 and HLA molecules for additional oncology, autoimmunity and virology applications.

The company operates a pre-revenue, clinical-stage business model with no commercial products approved; future revenue is expected to flow from commercialization of its therapeutic candidates upon regulatory approval. The company funds operations through venture capital and grant financing, having raised approximately $99 million across Series B rounds (a $49M round in January 2023 led by Pfizer Ventures and Earlybird, and a $50M expansion in May 2024 led by ICG Life Sciences), plus a £1.1M Innovate UK grant and a £2.5M Series A2 for ERAP2 development in August 2025. Clinical trials are conducted across 28 centers in Australia, France, Spain and the UK, with the company maintaining a wholly-owned Australian subsidiary. Leadership includes co-founder and CEO Peter Joyce (former Vertex Pharmaceuticals R&D Lead) and recently appointed Chair Edwin Moses, the executive previously responsible for the $4.8 billion sale of Ablynx NV to Sanofi.

The company's go-to-market is structured around clinical development and eventual commercialization through standard pharmaceutical channels. Strategic marketing focuses on scientific communication at major conferences (ASCO, ESMO), press engagement, and building relationships with clinical investigators, pharmaceutical partners, and the investment community. The company has secured a clinical supply agreement with Regeneron for GRWD5769 combination studies and a strategic partnership with Genomics Ltd to leverage large-scale genetic datasets for autoimmune patient stratification.

Short descriptiontext

Greywolf Therapeutics is a UK-based clinical-stage biotech developing first-in-class oral ERAP1 and ERAP2 inhibitors that modulate antigen presentation to treat solid tumors and autoimmune diseases, with two Phase 1/2 assets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMilton, United Kingdom
HQ citystring
Milton
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, antigen modulation technology, ERAP1 inhibitors, clinical-stage biotechnology, autoimmune disease treatments
Industry3 codes
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Immuno-oncology biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue expected from commercialization of novel antigen modulation therapies (GRWD5769 for oncology, GRWD0715 for autoimmunity) upon regulatory approval. The company is advancing through Phase 1/2 clinical trials with plans for Phase 2 and eventual market launch.

greywolftherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Greywolf Therapeutics is a clinical-stage biotech developing first-in-class oral small-molecule ERAP1 inhibitors that modulate antigen presentation on MHC-I molecules to control T-cell activation. Its lead clinical assets are GRWD5769 (oncology, for solid tumors in combination with anti-PD-1 therapy) and GRWD0715 (autoimmunity, for axial spondyloarthritis), supported by discovery programs targeting ERAP2 and HLA molecules.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 13-36% Objective Response Rate (ORR) across six solid tumor cohorts in patients with secondary anti-PD-1 resistance
+3 more records
Product overview1 text field

Greywolf Therapeutics is a clinical-stage biotech company developing novel antigen modulation treatments that control T cell activation by modulating antigen presentation. The company's portfolio consists of two clinical-stage ERAP1 inhibitors: GRWD5769 (first-in-class oral small molecule for solid tumors, currently in Phase 1/2) and GRWD0715 (selective oral small molecule for axial spondyloarthritis, in Phase 1/2). Both products work by inhibiting ERAP1 to alter the antigenic repertoire presented on cell surfaces, making tumors more visible to the immune system in oncology or preventing presentation of autoantigens in autoimmune diseases. The company also has discovery programs targeting ERAP2 and various HLA molecules (Classical HLA, Non-Classical HLA) for virology applications.

Product and service2 records
1GRWD5769
CategoryOncology therapeutic / Immuno-oncology
Description

GRWD5769 is a first-in-class oral small-molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) for treating advanced or metastatic solid tumors. Administered as an oral capsule in combination with cemiplimab (anti-PD-1), it generates alternating antigenic repertoires to broaden T-cell responses and prevent T-cell exhaustion. It is in Phase 1/2 clinical development.

2GRWD0715
CategoryAutoimmune disease therapeutic
Description

GRWD0715 is a first-in-class selective, potent oral small-molecule ERAP1 inhibitor designed to treat axial spondyloarthritis (axSpA) by interrupting autoantigen presentation and preventing damaging T-cell activation at the source of autoimmune disease. It is currently in Phase 1/2 clinical development.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Strategic partnership to study endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) and their role in autoimmune diseases. Genomics curates and analyzes large-scale genetic datasets to link ERAP enzyme variants with multiple autoimmune diseases, helping Greywolf identify patient populations for its autoimmune disease treatments including its Phase 1 program in axial spondyloarthritis.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Supply agreement for GRWD5769 clinical trial materials. Regeneron provides clinical trial supply of therapeutic agents for combination studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Greywolf Therapeutics

Immuno-oncology biopharmaceuticalsgreywolftherapeutics.com

Greywolf Therapeutics is a UK-based clinical-stage biotech developing first-in-class oral ERAP1 and ERAP2 inhibitors that modulate antigen presentation to treat solid tumors and autoimmune diseases, with two Phase 1/2 assets.

What Greywolf Therapeutics does

Greywolf Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Abingdon, UK, developing first-in-class oral small molecule inhibitors of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) — a novel antigen modulation approach that targets Signal 1 of T-cell activation, the initial step of antigen recognition that has been therapeutically unexplored to date. By inhibiting ERAP1, the company alters the peptide repertoire presented on MHC-I molecules, creating novel immunogenic peptides in oncology (making tumor cells more visible to the immune system) and suppressing autoantigen presentation in autoimmune disease. The pipeline comprises two clinical-stage assets: GRWD5769, an oral ERAP1 inhibitor in Phase 1/2 development (EMITT-1 trial) in combination with cemiplimab across six solid tumor indications including NSCLC, urothelial carcinoma, HCC, MSS-CRC, SCCHN and cervical cancer, demonstrating objective response rates of 13-36% in patients with secondary anti-PD-1 resistance; and GRWD0715, a selective ERAP1 inhibitor in Phase 1/2 (EAST-1) for axial spondyloarthritis. The company also has discovery programs targeting ERAP2 and HLA molecules for additional oncology, autoimmunity and virology applications.

The company operates a pre-revenue, clinical-stage business model with no commercial products approved; future revenue is expected to flow from commercialization of its therapeutic candidates upon regulatory approval. The company funds operations through venture capital and grant financing, having raised approximately $99 million across Series B rounds (a $49M round in January 2023 led by Pfizer Ventures and Earlybird, and a $50M expansion in May 2024 led by ICG Life Sciences), plus a £1.1M Innovate UK grant and a £2.5M Series A2 for ERAP2 development in August 2025. Clinical trials are conducted across 28 centers in Australia, France, Spain and the UK, with the company maintaining a wholly-owned Australian subsidiary. Leadership includes co-founder and CEO Peter Joyce (former Vertex Pharmaceuticals R&D Lead) and recently appointed Chair Edwin Moses, the executive previously responsible for the $4.8 billion sale of Ablynx NV to Sanofi.

The company's go-to-market is structured around clinical development and eventual commercialization through standard pharmaceutical channels. Strategic marketing focuses on scientific communication at major conferences (ASCO, ESMO), press engagement, and building relationships with clinical investigators, pharmaceutical partners, and the investment community. The company has secured a clinical supply agreement with Regeneron for GRWD5769 combination studies and a strategic partnership with Genomics Ltd to leverage large-scale genetic datasets for autoimmune patient stratification.

Greywolf Therapeutics firmographics

Firmographics
Name
Greywolf Therapeutics
Legal name
Grey Wolf Therapeutics Limited
Website
https://greywolftherapeutics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Greywolf Therapeutics is a UK-based clinical-stage biotech developing first-in-class oral ERAP1 and ERAP2 inhibitors that modulate antigen presentation to treat solid tumors and autoimmune diseases, with two Phase 1/2 assets.
Ownership category
akta.pro rank

Greywolf Therapeutics industry classification

Industry
Product category
Immuno-oncology biopharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immuno-oncology therapeutics
  • Antigen modulation technology
  • ERAP1 inhibitors
  • Clinical-stage biotechnology
  • Autoimmune disease treatments

Where Greywolf Therapeutics is headquartered

Location

Headquarters

HQ city
Milton
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Greywolf Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotech company. Revenue expected from commercialization of novel antigen modulation therapies (GRWD5769 for oncology, GRWD0715 for autoimmunity) upon regulatory approval. The company is advancing through Phase 1/2 clinical trials with plans for Phase 2 and eventual market launch.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Greywolf Therapeutics product offering

Product offering

Core offering

Greywolf Therapeutics is a clinical-stage biotech developing first-in-class oral small-molecule ERAP1 inhibitors that modulate antigen presentation on MHC-I molecules to control T-cell activation. Its lead clinical assets are GRWD5769 (oncology, for solid tumors in combination with anti-PD-1 therapy) and GRWD0715 (autoimmunity, for axial spondyloarthritis), supported by discovery programs targeting ERAP2 and HLA molecules.

Product overview

Greywolf Therapeutics is a clinical-stage biotech company developing novel antigen modulation treatments that control T cell activation by modulating antigen presentation. The company's portfolio consists of two clinical-stage ERAP1 inhibitors: GRWD5769 (first-in-class oral small molecule for solid tumors, currently in Phase 1/2) and GRWD0715 (selective oral small molecule for axial spondyloarthritis, in Phase 1/2). Both products work by inhibiting ERAP1 to alter the antigenic repertoire presented on cell surfaces, making tumors more visible to the immune system in oncology or preventing presentation of autoantigens in autoimmune diseases. The company also has discovery programs targeting ERAP2 and various HLA molecules (Classical HLA, Non-Classical HLA) for virology applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • GRWD5769 GRWD5769 is a first-in-class oral small-molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) for treating advanced or metastatic solid tumors. Administered as an oral capsule in combination with cemiplimab (anti-PD-1), it generates alternating antigenic repertoires to broaden T-cell responses and prevent T-cell exhaustion. It is in Phase 1/2 clinical development.
  • GRWD0715 GRWD0715 is a first-in-class selective, potent oral small-molecule ERAP1 inhibitor designed to treat axial spondyloarthritis (axSpA) by interrupting autoantigen presentation and preventing damaging T-cell activation at the source of autoimmune disease. It is currently in Phase 1/2 clinical development.

Quantifiable outcome

  • 13-36% Objective Response Rate (ORR) across six solid tumor cohorts in patients with secondary anti-PD-1 resistance
  • +3 more outcomes

Companies that use Greywolf Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Greywolf Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Greywolf Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Genomics LtdcoreStrategic or Co-development Partner · 29 April 2026Strategic partnership to study endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) and their role in autoimmune diseases. Genomics curates and analyzes large-scale genetic datasets to link ERAP enzyme variants with multiple autoimmune diseases, helping Greywolf identify patient populations for its autoimmune disease treatments including its Phase 1 program in axial spondyloarthritis.
  • RegeneronminorImplementation/ SI/ Consulting PartnerSupply agreement for GRWD5769 clinical trial materials. Regeneron provides clinical trial supply of therapeutic agents for combination studies.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Greywolf Therapeutics competitors and assessment

Company assessment

Market position

Strengths5 records

Competitive moat4 records

Key risks6 records

Customer concentration

Greywolf Therapeutics social profiles

Digital presence

Greywolf Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Greywolf Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Greywolf Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Greywolf Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Greywolf Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greywolf Therapeutics

What does Greywolf Therapeutics do?

Greywolf Therapeutics is a clinical-stage biotech developing first-in-class oral small-molecule ERAP1 inhibitors that modulate antigen presentation on MHC-I molecules to control T-cell activation. Its lead clinical assets are GRWD5769 (oncology, for solid tumors in combination with anti-PD-1 therapy) and GRWD0715 (autoimmunity, for axial spondyloarthritis), supported by discovery programs targeting ERAP2 and HLA molecules.

Is Greywolf Therapeutics a public or private company?

Greywolf Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Greywolf Therapeutics founded?

Greywolf Therapeutics was founded in 2017. It employs 51 to 100 people.

Where is Greywolf Therapeutics based?

Greywolf Therapeutics is headquartered in Milton, United Kingdom, in the Europe region.

How does Greywolf Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Does Greywolf Therapeutics have an API?

No public API is recorded for Greywolf Therapeutics.

What industry is Greywolf Therapeutics in?

Greywolf Therapeutics's product category is Immuno-oncology biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 5417 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceGreywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trialGreywolf Therapeutics dosed first participants with axial spondyloarthritis in the multiple ascending dose portion of its Phase 1/2 study, after completing the single ascending dose portion in healthy volunteers. The drug showed dose-proportional pharmacokinetics, clear ERAP1 target engagement, and no safety concerns. A US composition-of-matter patent was granted, and the placebo-controlled Phase 2a is planned for H2 2027.European BiotechnologyGreywolf reports early responses with oral ERAP1 inhibitor in solid tumoursGreywolf Therapeutics reported early clinical activity for its oral ERAP1 inhibitor GRWD5769 combined with cemiplimab in six solid tumour types, presenting Phase 1b data from the EMITT-1 trial at the 2026 ASCO Annual Meeting. Objective response rates ranged from 13% to 36%, with the highest in urothelial carcinoma (36%). The company is advancing the programme into Stage 2 cohort expansions for a randomised Phase 2 study.BioSpaceGreywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor typesGreywolf Therapeutics reported Phase 1b EMITT-1 trial data showing GRWD5769 plus cemiplimab achieved objective response rates of 13-36% and durable clinical benefit of 18-55% across six solid tumor types. The trial is ongoing, with the company advancing to Stage 2 cohort expansions for a randomized Phase 2 study.BioWorldGenomics and Greywolf partner in autoimmune diseasesGenomics Ltd. and Grey Wolf Therapeutics Ltd. have established a strategic relationship to develop first-in-class treatments for autoimmune diseases. The collaboration aims to create new therapies in this area.AijournGreywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune DiseasesGenomics and Greywolf Therapeutics announced a strategic partnership under which Genomics will analyze large-scale genetic datasets to link ERAP enzyme variants with multiple autoimmune diseases, with the resulting insights intended to guide Greywolf's autoimmune pipeline development. The collaboration leverages Genomics' genotype-phenotype data resource to identify and validate ERAP1 and ERAP2 as therapeutic targets for conditions including axial spondyloarthritis, inflammatory bowel disease, and psoriasis. Greywolf's autoimmune treatment candidate GRWD0715 is currently progressing through a Phase 1/2 trial, with plans to expand into additional autoimmune indications.PR NewswireGreywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune DiseasesGenomics announced a strategic partnership with clinical-stage biotech Greywolf Therapeutics to analyze large-scale genetic datasets evaluating how ERAP (Endoplasmic Reticulum Aminopeptidase) enzyme variants influence autoimmune disease risk across multiple conditions. The insights generated will guide Greywolf's selection of indication opportunities and strengthen its autoimmune disease pipeline, which includes a treatment currently in Phase 1/2 trials for axial spondyloarthritis. The collaboration leverages Genomics' proprietary genotype-phenotype data resource to identify and validate ERAP variants as therapeutic targets for conditions affecting approximately 1 in 10 people worldwide.BioSpaceGreywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune DiseasesGenomics and Greywolf Therapeutics announced a strategic partnership to analyze ERAP1 and ERAP2 genetic variants for autoimmune disease risk. The collaboration will use Genomics' large-scale genetic datasets to identify therapeutic targets, supporting Greywolf's pipeline. Greywolf's Phase 1/2 trial in axial spondyloarthritis is ongoing.GlobeNewswireGreywolf Therapeutics appoints Edwin Moses as ChairGreywolf Therapeutics, a clinical-stage biotech company based in Oxford, has appointed Edwin Moses as Chair of its Board of Directors. Moses brings over 30 years of board-level experience in life sciences, having previously built and sold Oxford Asymmetry International plc for £316 million and Ablynx NV for $4.8 billion, and having most recently led Dark Blue Therapeutics through its acquisition by Amgen for up to $840 million. The company stated that Moses joins at a pivotal stage as its oncology treatment candidate GRWD5769 advances through Phase 1/2 trials and its autoimmunity program GRWD0715 progresses in clinical development.BioSpaceGreywolf Therapeutics appoints Edwin Moses as ChairGreywolf Therapeutics appointed Edwin Moses as Chair of its Board of Directors, effective immediately. Moses, a serial entrepreneur, previously built Oxford Asymmetry and Ablynx, raising over $500 million, and served as Chair of Dark Blue Therapeutics, acquired by Amgen for up to $840 million. The company's oncology and autoimmunity treatments are advancing in clinical trials.